Malignant Fibrous Histiocytoma is an indication for drug development with over 20 pipeline drugs currently active. According to GlobalData, preregistered drugs for Malignant Fibrous Histiocytoma have a 100% likelihood of approval (LoA) indication benchmark. GlobalData’s report assesses how phase transition success rate (PTSR) and likelihood of approval (LoA) scores for pipeline drugs in Malignant Fibrous Histiocytoma compared to historical benchmarks. Buy the report here.

Smarter leaders trust GlobalData

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

Malignant Fibrous Histiocytoma overview

Malignant fibrous histiocytoma, now termed undifferentiated pleomorphic sarcoma (UPS), is thought to originate from primitive mesenchymal cells, emerging in soft tissue or bone, typically in the extremities or retroperitoneum. Most common in late adulthood, it exhibits a slight male predominance, constituting the most prevalent soft tissue sarcoma. The subtypes include storiform/pleomorphic, myxoid, giant cell, inflammatory, and angiomatoid. Diagnostic imaging, such as computed tomography (CT) or magnetic resonance imaging (MRI), aids in defining disease extent. Predominantly, the treatment approach involves surgical intervention due to the absence of a singular cure for this neoplasm categorized within the undifferentiated/unclassified sarcomas group.

For a complete picture of PTSR and LoA scores for drugs in Malignant Fibrous Histiocytoma, buy the report here.

Data Insights


The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article. 

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.